Hydration and Rate of Cesarean Delivery Among Nulliparous


The hypothesis of the present study is the hydration of nulliparous women with 250ml/hour vs. 125ml/hrs would decrease the rate of primary cesarean section.

Full Title of Study: “Intrapartum Hydration and Rate of Cesarean Delivery Among Nulliparous at > 37 Weeks: A Multicenter Randomized”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2018

Detailed Description

For this non-blinded randomized clinical trial (RCT) we will recruit approximately 670 women which meet the inclusion criteria across three sites (Eastern Virginia Medical School (EVMS), University of Arkansas for Medical Sciences (UAMS) and Obstetrix Medical Group, in California). When the patient is being scheduled for induction by her physician or when she presents to L&D for induction or in labor, but her cervical dilation on admission is less than 4 cm, the participants will be consented, and then randomized into a study intervention group. Both groups will receive maintenance IV hydration with Lactated Ringer's (LR) solution: Group I will receive LR at 125 ml/hr and group II will receive LR at 250ml/hr. Other than the rate of maintenance IV infusion, the two groups will receive routine intrapartum care.


  • Other: Routine
    • IV Hydration at 125 cc hour
  • Other: IV Hydration at 250cc hour
    • IV Hydration at 250 cc hour

Arms, Groups and Cohorts

  • Active Comparator: Routine
    • IV Hydration at 125 cc hour
  • Experimental: Intervention
    • IV Hydration at 250 cc hour

Clinical Trial Outcome Measures

Primary Measures

  • rate of cesarean section
    • Time Frame: 5 Years
    • The primary objective of this multi-center RCT is to determine if hydration with 250 ml/hr, when compared to traditional 125 ml/hr, significantly decreases the rate of primary cesarean delivery nulliparous.

Secondary Measures

  • labor
    • Time Frame: 5 Years
    • The secondary objectives of this randomized trial are to compare the 2 groups regarding: Time from randomization to delivery (minutes)

Participating in This Clinical Trial

Inclusion Criteria

• Non-anomalous singleton

  • Nulliparous (no prior delivery after 20 weeks) – Presenting at ≥37 weeks of gestation – Presenting for anticipated induction of labor or spontaneous labor (regular contractions for more than 2 hours), but cervical dilation less than 4 cm – Rupture of membranes – Expected to deliver at one of the participating hospitals Exclusion Criteria:

• Not in the inclusion criteria

  • Autoimmune disorders (antiphospholipid antibody, lupus, rheumatoid arthritis, scleroderma) – Diabetes mellitus-gestational or pre-gestational – Enrollment in another randomized clinical trial – Hematologic disorders (coagulation defects, sickle cell disease, thrombocytopenia, thrombophilia) – Hypertension (chronic or pregnancy induced) before randomization – HIV (human immunodeficiency virus) – Placenta previa / 3rd trimester bleeding – Renal insufficiency (serum creatinine > 1.5 mg/dL) – Restrictive lung disease – Seizure disorder on medication – Thyroid disease on medication – Any contraindications to vaginal delivery (breech, active herpes, schedule cesarean, abnormal fetal heart tracing)

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Chauhan, Suneet P., M.D.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Suneet P Chauhan, MD, Principal Investigator,
    • Andrew Combs, MD PhD, Principal Investigator, Obstetrix Medical Group
  • Overall Contact(s)
    • Suneet Chauhan, MD, 757-672-5955, mfmchauhan@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.